Skip to Main Content

Paper Details

Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma.
Front Oncol
32
2021
Autologous chimeric antigen receptor (CAR) T cells, CAR, CAR T-, CAR T-EGFRvIII, CAR T-EGFRvIII cells, EGFRvIII, EGFRvIII CAR T Cell, GBM, Glioblastoma, IDH1, chimeric antigen receptor, chimeric antigen receptor (CAR) T cells, epidermal growth factor receptor variant III, glioblastoma, patient, patients, rGBM, recurrent glioblastoma, tumor
Author NameAffiliation
John Y K LeePerelman School of Medicine at the University of Pennsylvania
Carl H JuneCenter for Cellular Immunotherapies, University of Pennsylvania
Carl H JunePerelman School of Medicine at the University of Pennsylvania
Zev A BinderThe Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Zev A BinderPerelman School of Medicine at the University of Pennsylvania
Donald M O'RourkeThe Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Donald M O'RourkePerelman School of Medicine at the University of Pennsylvania
  • 1 - 7

Datasets

Release 1.2